science & health•Mon, September 28, 2026•5 min read

The 'Young Blood' Myth: Why the FDA is Cracking Down on Anti-Aging Infusions

For years, companies have marketed 'young blood' plasma transfusions as a fountain of youth for the wealthy. Now, federal regulators are stepping in to warn that these costly treatments lack scientific backing and pose significant health risks.

The High Price of Unproven Promises

In recent years, a controversial trend emerged in the world of anti-aging: wealthy clients paying as much as $8,000 per liter for plasma harvested from young donors. Companies promised that these infusions could combat memory loss, Alzheimer’s, heart disease, and even multiple sclerosis. However, the FDA has officially intervened, labeling these practices a significant public health concern.

Federal regulators warn that the 'young blood' industry lacks clinical evidence and standard medical oversight.

What Does the FDA Say?

The FDA’s stance is firm: there is no evidence that infusions of plasma from young donors are effective at treating or preventing the signs of aging or age-related diseases. Beyond the lack of efficacy, the agency has expressed alarm over the safety and regulation of these procedures.

No established clinical benefit for the advertised anti-aging uses.
A lack of standardized dosing, frequency, or safety monitoring.
Concerns that patients are being targeted by 'unscrupulous actors'.
Potential risks that these unproven treatments may discourage patients from seeking established, effective medical care.

A Distorted View of Plasma Science

While plasma is a vital component of legitimate medical treatments—used effectively in hospitals for over a century—the 'young blood' industry has capitalized on the confusion between medical necessity and longevity marketing. In legitimate clinical settings, plasma is highly regulated to ensure safety and efficacy. Proponents of these fringe treatments, however, have ignored these regulatory standards, instead selling the fantasy that biological age can be reversed through simple infusions.

Simply put, we’re concerned that some patients are being preyed upon by unscrupulous actors touting treatments of plasma from young donors as cures and remedies.
— Scott Gottlieb and Peter Marks, FDA

Key Takeaways

The FDA warns that 'young blood' plasma infusions lack clinical evidence.
These treatments are being marketed at extremely high prices without regulatory approval for anti-aging.
Regulators warn that these procedures may be potentially harmful to patients.
The trend relies on exploiting medical terminology to appeal to those seeking longevity cures.
The FDA emphasizes that patients should avoid unproven treatments to prevent delay in receiving standard medical care.

FAQ

Does the FDA approve 'young blood' plasma transfusions for anti-aging?

No. The FDA has stated there is no clinical evidence that these infusions are effective for anti-aging or the treatment of age-related diseases.

Are plasma transfusions ever medically necessary?

Yes. Plasma is a standard tool in modern medicine for various legitimate conditions, and its use in hospital settings is strictly regulated.

Why is the FDA concerned about these treatments?

The agency is concerned that patients are being preyed upon by unscrupulous actors, paying for unsafe products, and potentially avoiding evidence-based medical treatments.

Are there known side effects to these infusions?

While the FDA has not detailed every potential side effect for these specific 'anti-aging' schemes, they have labeled the treatments 'potentially harmful' due to the lack of oversight and clinical testing.